Uncategorized

Capricor investor calls for change as company awaits decision on Duchenne candidate

Published

on

Kaos Capital in a letter to other Capricor Therapeutics shareholders called for “an immediate meeting, board change, and capital-preservation plan.” The biotech recently put all other pipeline work on pause as it awaits an Aug. 22 PDUFA date for embattled cell therapy deramiocel.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version